Study of Hepatitis Eradication Receiving Protease Inhibitor Administration

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

December 20, 2024

Study Completion Date

December 31, 2024

Conditions

Coronary Artery DiseaseMorality

Interventions

DRUG

glecaprevir/pibrentasivir

12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).

Trial Locations (1)

RECRUITING

Sentara Norfolk General Hospital, Norfolk

All Listed Sponsors

lead

Sentara Norfolk General Hospital

OTHER